126100-97-8

Usage

Uses

Used in Cognitive Enhancement:
Dimiracetam is used as a cognitive enhancer for its ability to improve memory formation and learning ability. It modulates the activity of neurotransmitters in the brain, such as acetylcholine and glutamate, leading to enhanced cognitive function.
Used in Neuroprotection:
Dimiracetam is used as a neuroprotective agent for its potential to prevent age-related cognitive decline and protect the brain from certain types of damage. Its neuroprotective properties may be beneficial in maintaining brain health and function.
Used in Pharmaceutical Industry:
Dimiracetam is used in the pharmaceutical industry as a potential therapeutic agent for cognitive disorders and neurodegenerative diseases. Its cognitive-enhancing and neuroprotective properties make it a promising candidate for the development of new treatments and interventions.
Used in Research and Development:
Dimiracetam is used in research and development for further exploration of its mechanisms of action and potential therapeutic applications. More studies are needed to fully understand its effects on cognitive function and neuroprotection, as well as to identify any potential side effects or limitations.

InChI:InChI=1/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9)

Upstream product

• 1668-10-6 glycinamide hydrochloride 
• 126101-13-1 2'-methylpropyl 3-oxopropionate 
• 153393-25-0 methyl 1-benzyl-4-oxo-2-imidazolidinepropanoate 

Downstream Products

• 126101-04-0 2,5-dioxohexahydro-1H-pyrrolo[1,2-a]imidazole-1-acetamide 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF DIMIRACETAM

The invention relates to a method of manufacture of dimiracetam (2,5-dioxohexahydro-1 H-pyrrolo[1,2-a]imidazole), characterized in that a 4-oxo-butanoic acid ester is condensed with glycinamide in a one-pot reaction with a controlled pH. The reaction may be performed in aqueous solution or in an anhydrous lower alcohol solution.

Synthesis and pharmacological activity of a series of dihydro-1H- pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers

A series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones were synthesized. These bicylic derivatives contain both the 2-pyrrolidinone and 4-imidazolidinone nuclei, already recognized as important for cognition enhancing activity. In addition, these structures maintain the backbone of piracetam and oxiracetam with the acetamide side chain restricted in a folded conformation. Their ability to reverse scopolamine-induced amnesia was assessed in a one trial, step-through, passive avoidance paradigm. The main features observed are a potent antiamnestic activity after ip administration (minimal effective dose being between 0.3 and 1 mg/kg ip for most compounds), the presence of a bell-shaped dose-response curve and, generally, a reduction of biological activity after po administration. However, the unsubstituted compound (15, dimiracetam) shows no evidence of a bell-shaped dose-response curve and completely retains activity when given orally, being 10-30 times more potent than the reference drug oxiracetam.

Psychotropic perhydroazacycloalka [1,2-A] imidazole derivatives

Imidazole derivatives are described which are useful in restoring learning and treating memory difficulties. A compound of the invention is 2,5-dioxohexahydro-1H-pyrrolo[1,2-a]imidazole.

Condensed imidazole derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them.

Compounds of structure (I) in which, R1 is hydrogen, C1 4alkyl, CHR6CONHR7 or CHR6COOR7 in which R6 and R7 are each hydrogen or C1 4alkyl; R2 is hydrogen, C1 5alkyl or a residue R2 of an amino acid R2 CH(NH2)COOH; R3 is hydrogen, C1 4alkyl, CONH2 or CO2R8 in which R8 is hydrogen or C1 4alkyl; and n is 2, 3 or 4, processes for their preparation, intermediates useful in their preparation, pharmaceutical composition containing them and their use in therapy as nootropic agents.